Premier Alternatives

Ribo Life Science

Suzhou, China · Founded 2007 · Publicly Held

Developer and provider of RNA interference ( RNAi ) technology designed to treat liver diseases. Ribo Life Science is based in Suzhou, China and was founded in 2007. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $1.2 billion (Jan 2026). It has raised $285 million.

Last price · $/share
—
Implied valuation
$1.2B
Total raised
$285.3M
Last round
—
No prints on record

No secondary trades in Ribo Life Science shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.

Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Ribo Life Science with a free account
  • ·The complete investor list: 12 names
  • ·Watch Ribo Life Science: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Where Ribo Life Science prices come from

Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Ribo Life Science stock.